SEZ6 Modulators Targeting Cancer Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments are ineffective in addressing relapsed or metastatic tumors, particularly in patients resistant to standard therapies, and fail to prevent recurrence and metastasis, highlighting the need for more targeted and potent therapies.
Innovation Solution
Development of SEZ6 modulators, including anti-SEZ6 antibodies and fusion constructs, that target tumor cells and cancer stem cells, associated with specific epitopes, and conjugated to cytotoxic agents to treat malignancies such as medullary thyroid cancer and small cell lung cancer, especially in patients resistant to platinum-based agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments (chemotherapy, radiotherapy, surgery) are used, then initial tumor control may be achieved, but the treatments fail to prevent relapse, tumor recurrence and metastases
Solution Approach 1:
The patent applies preliminary action by using SEZ6 modulators to target and eliminate cancer stem cells before they can cause relapse or metastasis. The modulators are designed to specifically recognize and bind to SEZ6 proteins expressed on cancer stem cells, initiating therapeutic action preemptively against potential disease progression rather than waiting for recurrent tumors to manifest.
Solution Approach 2:
The SEZ6 modulator acts as an intermediary between the immune system and cancer stem cells. These modulators (including antibodies and fusion constructs) serve as mediators that specifically target SEZ6-expressing cells, enabling the immune system to recognize and eliminate cancer stem cells that conventional therapies miss, thereby preventing recurrence and metastasis.
2Reliability
If standard therapies are applied to patients with relapsed or metastatic tumors, then initial treatment response may be observed, but the therapies become ineffective due to treatment resistance
Solution Approach 1:
The patent applies local quality by designing SEZ6 modulators with highly specific binding characteristics that target only SEZ6-expressing cancer stem cells, regardless of their resistance status to conventional therapies. This specificity allows the modulators to effectively treat resistant tumors by focusing therapeutic action precisely on the target population that conventional therapies fail to eliminate.
Solution Approach 2:
The patent employs parameter changes by developing modulators that target a different biological parameter (SEZ6 protein expression) compared to conventional therapies. By shifting the therapeutic target from general cancer cell markers to the specific SEZ6 marker on cancer stem cells, the treatment overcomes resistance mechanisms that developed against standard chemotherapy and radiotherapy approaches.
3Quantity of substance
If conventional treatments are used, then general tumor cell killing may occur, but tumor initiating cells (cancer stem cells) are not effectively targeted
Solution Approach 1:
The SEZ6 modulator serves as a specialized intermediary that enables precise identification and targeting of cancer stem cells. By binding specifically to SEZ6 proteins on these cells, the modulator acts as a mediator that directs therapeutic action exclusively to the tumor-initiating cell population, distinguishing them from conventional cancer cells that lack or have reduced SEZ6 expression.
Solution Approach 2:
The patent applies local quality through the design of SEZ6-modspecific binding domains in the modulators. These binding domains are engineered with high affinity and specificity for SEZ6 epitopes, creating a localized and precise targeting mechanism that concentrates therapeutic effect on cancer stem cells while sparing other cell types, thereby achieving both quantity reduction and high targeting precision simultaneously.
Data Source
AI summary
Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.